EMA CHMP recommends authorisation of AstraZeneca’s Evusheld for Covid-19
Pharmaceutical Technology
SEPTEMBER 19, 2022
Additionally, in the trial, the antibody cocktail was found to be well-tolerated. Evusheld is a cocktail of two long-acting antibodies, tixagevimab and cilgavimab. These antibodies are obtained from B-cells of convalescent Covid-19 patients. 5 variant, the company noted. 5 variant, the company noted.
Let's personalize your content